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Abstract
Inhalation of indium-containing dusts is associated with the development of indium lung disease. 
Workers may be exposed to several different chemical forms of indium; however, their lung 
dosimetry is not fully understood. We characterized the physicochemical properties and measured 
the lung dissolution kinetics of eight indium-containing dusts. Indium dissolution rates in artificial 
lung fluids spanned two orders of magnitude. We used the International Commission on 
Radiological Protection (ICRP) human respiratory model (HRTM) to estimate pulmonary indium 
deposition, retention and biokinetic clearance to blood. For a two-year (median workforce tenure 
at facility) exposure to respirable-sized particles of the indium materials, modeled indium 
clearance (>99.99% removed) from the alveolar-interstitial compartment was slow for all dusts; 
salts would clear in 4 years, sintered indium–tin oxide (ITO) would clear in 9 years, and indium 
oxide would require 48 years. For this scenario, the ICRP HRTM predicted that indium 
translocated to blood would be present in that compartment for 3.5–18 years after cessation of 
exposure, depending on the chemical form. For a 40-year exposure (working lifetime), clearance 
from the alveolar–interstitial compartment would require 5, 10 and 60 years for indium salts, 
sintered ITO and indium oxide, respectively and indium would be present in blood for 5–53 years 
after exposure. Consideration of differences in chemical forms of indium, dissolution rates, 
alveolar clearance and residence time in blood should be included in exposure assessment and 
epidemiological studies that rely on measures of total indium in air or blood to derive risk 
estimates.
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Introduction
Indium–tin oxide (ITO) has exceptional optical and electrical properties, which make it ideal 
for use as a transparent thin film conductor in consumer electronics. In commercial practice, 
indium oxide and tin oxide powders are blended, compacted and sintered to make ITO. Off-
specification or worn product and other indium-containing scrap materials are recycled to 
reclaim indium (Cummings et al., 2010; Miyauchi et al., 2012). During the production and 
reclamation of ITO, workers may inhale airborne dusts that contain indium metal, indium 
salts, indium hydroxide (In(OH)3), indium oxide (In2O3) and/or ITO (Choi et al., 2015; 
Chonan et al., 2007; Cummings et al., 2010; Hamaguchi et al., 2008; Homma et al., 2003, 
2005; Liu et al., 2012; Miyauchi et al., 2012; Nakano et al., 2009). Once inhaled, indium 
clears from the body slowly over time and hence persists in the body even after exposure 
ceases (Amata et al., 2015; Liu et al., 2016; Nakano et al., 2014). Some persons who inhale 
indium-containing dusts may develop indium lung disease, a severe and sometimes fatal 
condition characterized by pulmonary alveolar proteinosis (PAP), fibrosis and/or 
emphysema (Choi et al., 2013; Cummings et al., 2010; Homma et al., 2003; Liu et al., 2012; 
Nakano et al., 2016; Omae et al., 2011).
Epidemiologic studies have found adverse respiratory health outcomes associated with 
nonspecific exposure metrics, such as the concentration of indium in blood matrices or 
workplace air independent of chemical form (Chonan et al., 2007; Cummings et al., 2014, 
2016; Nakano et al., 2009). Limited evidence from the literature suggests that toxicity of 
indium compounds may be influenced by the particle size (as it relates to regional lung 
deposition) as well as the form of indium, its physicochemical properties and dissolution 
(biodurability) in lung fluids (Andersen et al., 2017; Badding et al., 2014; Gwinn et al., 
2013; Lim et al., 2014; Lison et al., 2009; Nagano et al., 2011; Tanaka et al., 2002, 2010). 
Unfortunately, little is understood or known about the physicochemical properties and 
dissolution behavior of real-world indium-containing dusts to which workers are exposed 
(Omae et al., 2011). Such data are necessary to better understand inhaled dose and disease 
risk from exposure to indium. In this study, we characterized the physicochemical properties 
and measured the dissolution of indium from particles encountered during the production 
and reclamation of ITO in artificial lung fluids and used this data to model deposition and 
time-dependent pulmonary indium, clearance and retention to illustrate the effects of 
dissolution characteristics of the chemical forms of indium on dose estimates.
Materials and methods
Eight study materials were collected from a facility that produces ITO and where two 
workers developed PAP (Cummings et al., 2010). At this facility, In(OH)3 powder is used to 
make In2O3 powder which is mixed with tin oxide (SnO2) powder and homogenized. The 
homogenized material is then formed into a desired shape. These unsintered shapes are 
sanded and then fired to produce sintered ITO. The sintered ITO shapes are machined to 
final dimensional specifications. Product that does not meet specifications, indium-
containing wastes and worn product purchased back from customers are reclaimed by a 
proprietary process.
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Study powder characterization
Eight indium-containing materials were collected at the facility as reported in a previous 
study (Badding et al., 2014). Three bulk materials were collected from the refinery 
(feedstock In(OH)3, In2O3 and SnO2 powders) at this facility. Two bulk material samples 
were collected from production processes: unsintered ITO (UITO) dust from a sanding 
operation and sintered ITO (SITO) dust from a machining operation. Three additional bulk 
materials were collected from the reclamation process: a mixture of waste sintered and 
unsintered (SUITO) dust, aerosol particles captured in a ventilation dust (VD) collector and 
reclaim by-product (RB) dust (Badding et al., 2014).
Particle size, density, surface area and surface chemistry of these materials were summarized 
previously (Badding et al., 2014). For the current study, materials were additionally 
characterized using scanning electron microscopy (SEM) with semiquantitative energy-
dispersive X-ray analysis (EDX) to identify elemental constituents and with powder X-ray 
diffraction to identify crystalline constituents and specific phases (EB Scientific Enterprises, 
Golden, CO). Phase identifications were made by comparing the measured diffraction 
spectra to patterns in the International Centre for Diffraction Data Powder Diffraction File 
(ICDD, Newtown Square, MA) and to pertinent literature. The mass fraction of powder that 
was elemental indium and/or tin was determined using proton-induced X-ray emission 
(PIXE) spectroscopy (Elemental Analysis Corp., Lexington, KY).
Biodurability in artificial lung fluids
To evaluate the dissolution of indium and tin from particles that are inhaled and deposited in 
the conducting airways, we used a model of airway epithelial-lining fluid referred to as 
serum ultrafiltrate (SUF) (Finch et al., 1988). This formulation includes sodium citrate and 
the chelator DTPA, originally added to ensure that dissolved trivalent cations remained in 
solution. Results of animal studies (Gwinn et al., 2013; Nagano et al., 2011; Tanaka et al., 
2002), cellular in vitro studies (Gwinn et al., 2013) and human lung biopsy specimens 
(Homma et al., 2003) indicate that indium-containing particles with size capable of 
penetrating to the alveolar region of the lung are engulfed and sequestered by macrophages. 
As such, dissolution of indium from particles was also evaluated using phagolysosomal 
simulant fluid (PSF) to mimic the acidic environment inside of alveolar macrophage 
phagolysosomes (Stefaniak et al., 2005). In a preliminary study with PSF, it was observed 
that up to 70% of a dissolved indium standard adhered to the containers used to perform the 
dissolution experiment and for sample storage prior to quantification; however, when sodium 
citrate and DTPA were added to PSF (at the same concentrations as prescribed for SUF), 
recovery of the indium standard was 90%. Hence, the PSF formulation originally described 
by Stefaniak et al. (2005) was modified to include sodium citrate (0.0588 g/L) and DTPA 
(0.0787 g/L) for all dissolution studies.
Each study material was evaluated using the well-established static dissolution technique as 
described previously (Kanapilly et al., 1973). A known mass of powder was weighed in a 
static dissolution chamber and each chamber immersed in 80 mL of artificial lung fluid 
maintained at 37 °C to mimic lung temperature. The SUF solvent was maintained at pH 7.4 
± 0.2 using 5% CO2/95% air and samples of the liquid were collected at 3, 6, 12, 24, 48, 96 
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and 168 h. The PSF solvent remained at pH 4.5 ± 0.1 and samples were collected at 3, 6, 12, 
18, 24, 48 and 96 h then weekly for 28 days to simulate long-term phagolysosomal 
sequestration during the lifespan of alveolar macrophages. Triplicate samples of each study 
material and field blanks (dissolution chambers without powder) were prepared for each 
dissolution experiment.
The initial mass of elemental indium and/or tin in each sample was calculated as the product 
of powder mass weighed into each dissolution chamber multiplied by the fraction of metal 
determined by PIXE analysis. Artificial lung fluid samples were analyzed without digestion 
to quantify the mass of dissolved metal using inductively coupled plasma-optical emission 
spectroscopy (ICP-OES). The matrix-specific limit of detection (LOD) and limit of 
quantification (LOQ) for indium were 10 and 48 μg/L (SUF) and 6 and 20 μg/L (PSF). For 
tin in SUF, the LOD and LOQ values were 10 and 47 μg/L (SUF). Note that based on the 
results from the study with SUF, it was observed that the dissolution of indium from 
particles was independent of the dissolution of tin (data not shown). Recently, Andersen et 
al. reported that the dissolution of indium and tin were independent from ITO particles 
(Andersen et al., 2017). Given that there was no interference with indium dissolution, tin 
was not quantified in the study with PSF. Neither indium nor tin was detected in any of the 
field or reagent blank samples.
For each material, values of the mass fraction of material remaining were plotted versus time 
and multiple-component negative exponential functions fitted to the data using the Proc 
NLIN procedure in SAS version 9.3 (SAS Institute, Cary, NC) and Sigma Plot version 12.5 
(Systat Software Inc., San Jose, CA) (Chazel et al., 2000):
(1)
where f = the proportion of the total element dissolved in the initial rapid (fr) or latter slower 
(fs =1 − fr) dissolution phase, s = the dissolution rate for the initial rapid (sr) or latter slower 
(ss) phase in d−1 and t = elapsed time (d). Values of fr and fs were determined from the 
intercepts of the fitted curves. The material fractional dissolution rates (sr and si) were equal 
to the slopes of the fitted curves. Particle dissolution half-times (t1/2) were calculated from 
the relationship .
Lung dosimetry modeling
A major objective of this study was to highlight the effect of material form on dose. Though 
particle size distribution, density and other physical factors are important for estimating 
pulmonary deposition, the focus herein was not to estimate dose in a specific region of the 
lung to evaluate some toxicological end point, rather it was to illustrate the effect of 
chemical form and its importance for exposure assessment and generation of metrics for 
epidemiologic studies. To achieve this objective, particle deposition and clearance in the 
respiratory tract were modeled using the Activity and Internal Dose Estimates (AIDE) 
software (Bertelli et al., 2008). The software uses the International Commission on 
Radiological Protection (ICRP) human respiratory tract model (HRTM) to calculate the 
mass of indium remaining in the different respiratory tract compartments (lung burden) and 
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accounts for mechanical clearance and dissolution clearance in biological fluids (ICRP, 
1994). The ICRP model uses a simplistic lung morphometry assuming the lung acts as a 
series of filters that dictate regional lung deposition for particles across a range of sizes 
(Supplemental Figure S1a). Since clearance from the tracheobronchial and head airways 
compartments are relatively rapid and indium lung disease is manifest primarily in the 
alveoli, we focused on long-term dose from exposure to respirable size particles, that is, 
mass median aerodynamic diameter (MMAD) = 4 and geometric standard deviation (GSD) 
= 2.5. Rather than use the ICRP default MMAD of 5 μm, we defined respirable size particles 
as having a MMAD of 4 μm based on the convention for “respirable” air samplers, which 
have a 50% collection efficiency at that diameter (Lippman, 1999). In this situation, the 
GSD of 2.5 has more influence than the MMAD in modeled particle lung deposition. For 
example, at a GSD of 2.5 the alveolar regional deposition (compartment of interest for 
indium lung disease) values are 9.9% and 9.6% for 4 and 5 μm particles, respectively. Note 
that in addition to the size distribution, density can exert significant influence on particle 
regional lung deposition, especially for scenarios in which particle sizes are small and in the 
Stokes regime (Miller et al., 2013). A range of densities were previously measured for the 
indium study materials (Badding et al., 2014). For the case when the exposure material is 
In2O3 particles with a density of 7.18 g/cm3, then a particle with aerodynamic diameter of 4 
μm will have a physical particle size of 1.44 μm. At the lower end of measured densities, if 
the exposure material is particles of In(OH)3 with a density of 4.38 g/cm3, then the physical 
diameter for these lower density particles is 1.87 μm. Hence, in this situation, for the indium 
facility under study, even though the different densities of these materials results in different 
physical diameters for particles of the same aerodynamic diameter, those particles will 
behave the same in terms of their regional deposition in the human respiratory tract. For 
mechanical clearance, the default rate constants were obtained from the ICRP HRTM (see 
Supplemental Figure S1b). For the biokinetic components of the model, additional code was 
obtained from the author of the software to implement the systemic distribution and 
clearance of indium by ICRP 30. The fractional coefficients were: marrow 0.3, liver 0.2, 
kidney 0.07, spleen 0.02 and other organs 0.41 with indefinite retention in the organs (ICRP, 
1981). Hoet et al. and Castronovo and Wegner reported that indium kinetics in the blood 
followed a biphasic clearance with half-lives of 1.9 to 2.8 days for the fast phase and 60 to 
69 days for the slow phase (Castronovo & Wagner, 1973; Hoet et al., 2012). Thus, rather 
than using a fractional clearance rate for indium in blood of 2.77 d−1 (half-life of 0.25 days) 
we used 0.011 d−1 (half-life of 65 days) as the slower rate is more consistent with the 
protracted release of poorly soluble forms of indium from the lungs as well as evidence from 
human data showing prolonged presence of indium in blood years after the cessation of 
exposure (further, the software cannot accommodate biphasic clearance) (Hoet et al., 2012). 
The use of a single clearance rate constant of 0.011 d−1 provides a reasonable estimate for 
modeling clearance from the respiratory tract of both acutely and chronically exposed 
workers. For chemical clearance (see Supplemental Figure S1c), the material-specific 
indium dissolution rates (d−1) and fractions were obtained from the dissolution studies. The 
AIDE software only permits input of a single set of dissolution parameters for all respiratory 
compartments. For modeling purposes, we used the rates and fractions determined from the 
PSF studies because, as noted above, indium lung disease is primarily manifest in the 
alveoli.
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Modeling was performed assuming a reference worker at light work, breathing through their 
nose only and following a pattern of 8 h of exposure (deposition and clearance) followed by 
16 h of clearance each day for 5 work days followed by 2 days off representing clearance 
only. Two exposure scenarios were modeled. In the first, exposure duration was taken to be 2 
years, the median tenure for the workforce at this facility (Cummings et al., 2014), followed 
by a clearance period of 53 years. In the second scenario, exposure duration was 40 years 
(working lifetime) followed by a clearance period of 15 years for the faster clearing VD dust 
to 60 years for the slower clearing indium oxide. For the purposes of this study, clearance 
was considered to be complete when the amount of indium remaining in a respiratory tract 
compartment or blood reached 0.01% of the initial mass inhaled. Though we focused on a 
light work scenario as this is the predominate type of work at this facility, breathing rate 
influences deposition and the same scenarios described herein were modeled for a heavy 
breathing (100% nose breather) worker and results are provided in Supplemental File 2. The 
mass fraction of indium distributed among various respiratory tract compartments and to 
blood were plotted against time using Sigma Plot to explore dose and retention patterns for 
the different exposure scenarios.
Results
Differences in physicochemical properties among forms of indium encountered in the 
workplace translated into differences in observed indium dissolution from the study samples, 
which in turn, influenced lung dose and clearance kinetics.
Study powder characteristics
All bulk materials were composed of particles with sizes capable of penetrating to the 
alveolar region of the lung (Badding et al., 2014). On the surfaces of the three ITO materials, 
indium was present as a mixture of indium metal (In0) and In2O3 at similar proportions; tin 
was present in the form of SnO (not SnO2). The VD collector and RB particle surfaces were 
consistent with indium salt and In2O3 (also In0 on the surface of the RB dust). Elemental 
analysis by EDX confirmed that the feedstock powders were high purity (i.e. indium to 
oxygen ratios approached values expected from stoichiometry). Assuming that the ITO 
powders were a 90:10 mixture of In2O3 and SnO2, the ratios of indium to oxygen and tin to 
oxygen also indicated high-purity materials. The VD particles gave strong EDX signals 
indicating that this material contained an indium salt and the RB dust produced weaker 
signals indicative of lower amounts of the indium salt. From X-ray diffraction analysis, the 
feedstock indium hydroxide, indium oxide and tin oxide were pure crystalline In(OH)3, 
In2O3 and SnO2, respectively. All ITO materials were crystalline cubic In2O3 and SnO2. The 
particles from the VD collector contained crystalline In2O3. The diffraction pattern of RB 
dust was consistent with a highly crystalline material though none of the peaks matched 
reference patterns for In2O3, SnO2 or ITO. PIXE analysis revealed that the indium or tin 
content of the feedstock powders matched values based on stoichiometry. Levels of indium 
in the ITOs were similar. Among the eight study materials, levels of tin ranged from 0.3% 
(VD) to 8% (SUITO, SITO).
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Dissolution in simulated lung fluids
As shown in Figure 1(a–c), dissolution of indium from all indium-containing study powders 
in SUF was biphasic, that is, consisted of an initial rapid phase followed by a later slower 
phase. Tin dissolution followed the same bi-phasic pattern (data not shown). In SUF, the 
total mass of indium dissolved was greatest from the VD and RB materials (Figure 1(a)), 
intermediate for In(OH3), UITO and SITO (Figure 1(b)) and least for In2O3 and SUITO 
(Figure 1(c)). Interestingly, the mass fractions of dissolved indium differed among the ITOs 
despite having the same crystalline phase of indium and nearly identical surface and bulk 
chemistries. As shown in Table 1, the rank order of specific surface areas of the ITOs were 
(from highest to lowest) UITO >SITO >SUITO. Hence, the greater the available surface area 
for solvation, the more indium that dissolved, which explains the observed differences in 
fractional dissolution rates among the ITO materials. Table 1 summarizes the cumulative 
amount of indium and/or tin dissolved, and the fitted dissolution parameters (fr, fs, sr and ss) 
for the industrially sampled powders in SUF. The calculated values of sr for indium varied 
from 0.25 to 6.15 d−1 among study materials. Values of ss for indium spanned two orders of 
magnitude.
Based on the SUF data, three representative indium-containing materials that spanned the 
range of observed solubilities (VD, SITO and In2O3) were further evaluated in PSF to 
understand the alveolar fate of indium. As shown in Figure 1(d), in PSF dissolution of 
indium from In2O3, SITO and VD particles was biphasic. As summarized in Table 2, the 
mass fractions of indium that dissolved differed by material and followed the rank order 
(from greatest to least): VD >SITO >In2O3. For each material tested in the acidic PSF 
model, the mass fraction of indium dissolved was greater than in SUF at near-neutral pH. 
Table 2 also summarizes the fitted dissolution parameters for these materials that were used 
to model lung dosimetry.
Lung dose metrics
Figure 2(a) is a plot of alveolar indium retention predicted by the ICRP HRTM for a two-
year (median tenure) exposure to respirable sized particles of In2O3, SITO and VD particles. 
The clearance aspect of the model includes the contributions from both indium chemical 
dissolution (as measured in PSF) and mechanical particle removal mechanisms (i.e. particle 
biopersistence). From this plot, indium lung clearance rates in the alveolar compartment 
were slow for all study powders though long-term indium retention differed among chemical 
forms. Specifically, three distinct alveolar retention profiles for indium were evident. 
Following cessation of exposure, indium in the form of salts in VD particles would need 4 
years to clear, indium in the form of SITO would clear in 9 years and indium as In2O3 would 
require 48 years.
Of interest is the slow clearance of indium from blood following a two-year exposure as 
shown in Figure 2(b) because this matrix is often used as a biological marker of exposure 
(Harvey et al., 2016). In the ICRP HRTM, indium clearance to blood is a reflection of only 
the chemical dissolution rate. Note that our modeling results are based only on 
measurements in PSF because our emphasis was on alveolar aspects of indium lung disease 
and in vivo dissolution in the airway lining fluid (mimicked by SUF) is only relevant for the 
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first few days following particle deposition, as such, dissolution by alveolar macrophages 
(mimicked by PSF) would mainly contribute to indium clearance to blood. The ICRP model 
predicted that following two years of exposure to indium in the form of VD, SITO and In2O3 
indium would remain in blood for 3.5, 6.5 and 18 years, respectively and is systemically 
distributed to other organs in the body over time.
For a 40-year exposure (Figure 2(c)), the ICRP HRTM predicted that indium would quickly 
accumulate in the alveoli before reaching a plateau. The same three general alveolar 
retention profiles by chemical form of indium compound were also observed for a 40-year 
exposure. After cessation of 40 years of exposure, the model predicted it would take 5 years 
to clear the indium from the alveoli for VD particles, 10 years for SITO particles and 60 
years for In2O3.
Figure 2(d) presents plots of blood indium retention predicted by the ICRP model for a 40-
year (working lifetime) exposure to respirable size particles. For this scenario, the model 
predicted that following exposure to indium in the form of VD, SITO and In2O3 indium 
would remain in blood for 5, 10 and 53 years, respectively.
The model results presented in Figure 2 are for a reference worker at light work; however, 
some jobs at this facility require more exertion, which will affect breathing patterns and 
therefore particle deposition and indium retention. To understand the influence of work 
pattern on indium retention, we modeled alveolar and plasma indium on fractional retention 
for VD, SITO and In2O3 indium dusts under heavy exercise and 100% nose breather (see 
Figure S1 in the Supplemental File) for the same 2- and 40-year exposure scenarios as 
described earlier. Among the forms of indium dusts, for the 2-year exposure scenario, heavy 
exercise increased indium retention in the alveoli by 31–36% compared to light work and 
increased plasma retention by 22–35%. For the 40-year exposure scenario, heavy exercise 
increased indium retention in the alveoli by 34–37% and indium retention in the plasma by 
24–35%.
Discussion
Workers engaged in the production and reclamation of ITO are potentially exposed to 
indium having a variety of chemical forms (Choi et al., 2015; Chonan et al., 2007; 
Cummings et al., 2010; Hamaguchi et al., 2008; Homma et al., 2003, 2005; Liu et al., 2012; 
Miyauchi et al., 2012; Nakano et al., 2009). Our in vitro experiments demonstrated that 
indium was released from all tested study materials using SUF or PSF artificial lung fluids 
and that observed differences in dissolution rates could be attributed to the chemical form of 
indium in the dust. For example, the VD and RB dusts which contained indium in the form 
of a salt were most soluble, whereas the feedstock In2O3 which contained highly crystalline 
In2O3 was the least soluble.
Previously, it was reported that commercially available unsintered ITO particles were rapidly 
engulfed by the RAW 264.7 macrophage cell line in vitro (Gwinn et al., 2013). Rapid uptake 
by macrophages of the same indium-containing particles used in the present study was 
confirmed in vitro (Badding et al., 2015). In the study of commercially available unsintered 
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ITO particles, Gwinn et al. measured ionic indium in culture media following particle uptake 
and reported that dissolution in macrophage phagolysosomes was a key driver for 
cytotoxicity (Gwinn et al., 2013). In a follow-on study by the same group, macrophage-
mediated dissolution of sintered ITO particles and indium phosphide particles was reported 
to predict pulmonary toxicity in vivo (Gwinn et al., 2015). In a study of In2O3 nanoparticles, 
it was reported that the slow in vitro indium dissolution rate observed in artificial 
phagolysosomal fluid (pH 5.5) was consistent with the in vivo persistence of these particles 
in rats and the time course of development of PAP (Jeong et al., 2016). In our study, we also 
observed faster indium dissolution under acidic conditions (pH 4.5) compared to near-
neutral conditions (pH 7.4) and Andersen et al. recently reported the same observation for a 
commercially available ITO powder (Andersen et al., 2017). Collectively, these data indicate 
that in the tracheobronchial (conducting airways) region, clearance by mechanical processes 
will dominate whereas in the nonciliated alveolar region of the lung, chemical dissolution 
inside macrophage phagolysosomes will contribute more to clearance. Regardless of lung 
fluid model, the indium-containing dusts exhibited three distinct categories of low, 
intermediate, and somewhat higher solubility (Figure 1) which indicates that indium 
retention in the lung differs among chemical forms and their physicochemical properties. A 
recent study by Badding et al. revealed differences in plasma indium concentrations over a 
time course of 90 days in rats exposed to a bolus intratracheal instillation dose of the In2O3, 
SITO and VD particles used in the current study (Badding et al., 2016). Substantially larger 
concentrations of indium were detected in early blood measurements (days 1 and 7) with 
VD exposure versus In2O3 or SITO, which may reflect the enhanced dissolution of indium 
from those particles. Furthermore, the same dose level of In2O3 resulted in negligible 
amounts of blood indium, suggesting slow indium dissolution in the lungs of rats.
Available case reports and epidemiological studies indicate that persons who inhale indium-
containing dusts may develop indium lung disease (Choi et al., 2013; Cummings et al., 
2010; Homma et al., 2003; Liu et al., 2012; Nakano et al., 2016; Omae et al., 2011); 
however, disease has not been causally linked to a specific chemical form of indium. 
Specifically, it is unclear if all forms of indium are capable of inducing PAP and fibrosis, and 
therefore, pose the same disease risk. Prior to this report, little was known about the 
physicochemical properties and dissolution behavior of real-world indium-containing dusts 
to which workers were exposed. Our data document five different chemical forms of indium 
(salts, metal, hydroxide, oxide or alloyed with tin) present in various dusts encountered 
during production and reclamation of ITO at one facility. Use of the ICRP HRTM enabled us 
to predict pulmonary retention based on material-specific dissolution parameters and 
mechanical clearance mechanisms. All chemical forms of indium required years to clear 
from the lung after cessation of exposure (Figure 2). Notably, clearance rates were slowest 
from the alveolar lung compartment, which is the site of clinical manifestation for indium 
lung disease (Cummings et al., 2012). If a long-term indium burden in the lung contributes 
to indium lung disease, particularly advanced findings of fibrosis and emphysema 
(Cummings et al., 2012; Nakano et al., 2014), then our data suggest that all forms of indium 
identified in these dusts may contribute to burden and pose a health risk. Indeed, fibrotic 
lesions were evident in the lungs of rats exposed to indium-containing particles with a range 
of dissolution rates (In2O3, SITO, or VD) (Badding et al., 2016). However, the 
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histopathological analysis suggested differential severity, with rats exposed to SITO and VD 
scoring higher for PAP and fibrosis compared to In2O3 at the same dose. Alternatively, if 
intra-alveolar accumulation of surfactant and impairment of lung function characteristic of 
indium lung disease is triggered by a specific underlying mechanism, then perhaps only 
specific forms of indium could induce such reactions. Findings from our in vitro (Badding et 
al., 2015) and in vivo (Badding et al., 2016) studies have demonstrated compromised 
phagocytic function of macrophages following exposure to SITO and VD particles but not 
with other indium-containing particles. Given that impaired phagocytosis contributes to 
disturbed surfactant homeostasis and has been implicated in PAP (Greenhill & Kotton, 2009; 
Kitamura et al., 1999), macrophage dysfunction may be a key initiator in the pathogenesis of 
indium lung disease. It is worth mentioning that available literature documents the presence 
of indium-containing particulate in lung tissue of exposed workers and biopsy specimens of 
experimental animals for months to years after last exposure (Badding et al., 2016; Hoet et 
al., 2012; Homma et al., 2003; Tanaka et al., 2010). Our dissolution data (Tables 2 and 3) 
confirm that indium-containing particles encountered during production and reclamation of 
ITO are biodurable in the lung and can persist in the alveoli for years after cessation of 
exposure. Note that the actual persistence of indium in the lung (and blood) may be different 
than predicted by HRTM because the model does not account for impaired mechanical 
clearance due to macrophage dysfunction or cytotoxicity from dissolution of indium.
Finally, the regional lung compartment and blood clearance rates predicted from the in vitro 
dissolution data has implications for biomonitoring. Measurements of indium in whole 
blood, plasma or serum are often used as indices of inhalational exposure (Choi et al., 2013; 
Chonan et al., 2007; Cummings et al., 2014; Hamaguchi et al., 2008; Harvey et al., 2016; 
Hoet et al., 2012; Homma et al., 2003, 2005; Iwasawa et al., 2017; Liao et al., 2004; Liu et 
al., 2012; Miyaki et al., 2003; Nakano et al., 2009). The underlying premise of these 
biomarkers is that indium-containing particles that deposit in the lung undergo dissolution 
and the solubilized indium ions are transferred to blood and excreted so they can be used as 
a measure of exposure (properly accounting for exposure and work history). Our dissolution 
and clearance data indicate several important points that must be considered when 
interpreting indium biomonitoring results from blood matrices: (1) all forms of indium 
encountered in a workplace will contribute to blood indium burden, though at different rates; 
(2) the concentration of indium in blood is influenced by the chemical form of indium to 
which a worker is exposed and by the burden of indium in the lungs; and (3) indium 
clearance from blood occurs over a period of years and is therefore not an indicator of 
current exposure. The importance of this latter point is highlighted by a report that the 
clearance half-time for indium in serum was 8.1 years in former workers (Amata et al., 
2015). As such, these data present an initial effort to provide a dissolution-based explanation 
as to why blood indium levels may not directly relate to current airborne exposure (Hoet et 
al., 2012) and thus may not be representative of lung dose over shorter time periods, 
particularly in workers with longer employment tenure.
Our software model can only use one set of dissolution parameters and by choosing the 
faster PSF values to predict clearance it can result in an over estimation of dissolution 
clearance and slightly over estimate blood levels. On the other hand, clearance from blood 
only is based on the slower rate of the biphasic clearance which accounts for 69% of the 
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clearance, thus leading to under estimation of the dissolution clearance (Castronovo & 
Wagner, 1973). Moreover, the ICRP model assumes indefinite retention in the organs; 
however, an animal experiment by Hoet et al. 2012 (and citations therein of previous short-
term exposure studies by Castronovo and Wagner) using a single exposure to In2O3 
(pharyngeal aspiration) or InCl3 (intraperitoneal injection) suggested there was evidence of a 
systemic depot in the organs which may contribute to blood indium levels which is not 
accounted for in this model (Hoet et al., 2012). Additionally, the fractional distribution of 
indium in the different organs are not consistent between the ICRP model and experimental 
studies by Hoet et al. and Castonovo and Wagner (Castronovo & Wagner, 1973; Hoet et al., 
2012). The foregoing evidence suggests that, at this time, there are limitations with modeling 
blood indium values, though the overall patterns over time are informative and useful in 
interpreting biomonitoring data. For more realistic modeling of expected blood content 
under different exposure and work history scenarios, a more accurate physiologically based 
pharmacokinetic model is needed that accounts for contributions from systemic organs and 
indium recycling biokinetics.
In epidemiologic studies of chronic diseases, especially of cancer outcomes, cumulative 
exposure is an effective summary metric used in exposure-response models (Kriebel et al., 
2007), but its use in noncancer outcomes is called to question (de Vocht et al., 2015). 
Cumulative exposure is based on several assumptions about the exposure disease association 
including a linear accumulation of dose at the target tissue (Smith, 1992). In this study, dose 
modeling for 40 years suggest that in the alveoli, an equilibrium (between accumulation and 
clearance) is reached with these poorly soluble materials in less than 10 years; dose does not 
increase infinitely with time. Cumulative exposure over periods longer than 10 years will 
likely overestimate exposure, which in turn will underestimate the measure of risk and 
flatten the exposure-response curve at the higher concentrations of cumulative exposure. 
Thus, dissolution characteristics can inform the creation of exposure metrics for use in 
epidemiologic studies. Moreover, the dose profile over time permits different exposure 
metrics to be created to explore different disease mechanisms and exposure response 
relationships.
Conclusions
Consistent with our hypothesis, differences in physicochemical properties of the indium-
containing study materials evaluated herein translated into differences in dissolution and 
biokinetic behavior. Using the ICRP HRTM, three distinct alveolar clearance profiles were 
evident: indium in the form of salts from reclamation operations would clear fastest, 
followed by indium in the form of less soluble In(OH)3, SITO and UITO and finally indium 
in the form of least soluble In2O3 and SUITO. The clearance of indium to blood was 
predicted to result in persistence in that compartment for years since last exposure and its 
retention depended on the chemical form of indium exposure material. We conclude that not 
all chemical forms of indium will dissolve and clear in the same manner, which is an 
important consideration for exposure assessment and epidemiological studies of indium 
workers that rely on measures of total indium in air or blood to derive risk estimates.
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Figure 1. 
Dissolution kinetics of indium in artificial lung fluids. Dissolution in SUF (pH 7.4) was 
biphasic and the mass fraction of indium that dissolved was: (a) greatest for VD and RB; (b) 
intermediate for In(OH)3, SITO and UITO; and (c) least for In2O3 and SUITO. In PSF (pH 
4.5), dissolution of In2O3 and SITO was linear and for VD it was biphasic; the mass 
fractions of indium dissolved were as follows: (d) VD >SITO >In2O3. Line in each plot for 
each material is the average fitted curve for n = 3 samples.
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Figure 2. 
Clearance predicted by the ICRP HRTM for respirable size particles of each study powder 
for a reference human at light work. Two-year exposure: (a) lung alveoli, (b) blood. Forty-
year exposure: (c) lung alveoli, (d) blood.
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r l
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 p
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=
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=
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O
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at
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re
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 r
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 c
on
sid
er
at
io
ns
.
d C
um
 =
 c
um
ul
at
iv
e 
to
ta
l e
le
m
en
ta
l m
as
s d
iss
ol
ve
d 
du
rin
g 
se
v
en
-d
ay
 st
ud
y 
pe
rio
d.
e F
itt
ed
 m
od
el
 d
id
 n
ot
 c
on
v
er
ge
 fo
r a
ll 
re
pl
ic
at
e 
sa
m
pl
es
 so
 p
ar
am
et
er
 e
sti
m
at
es
 w
er
e 
ca
lc
ul
at
ed
 u
sin
g 
re
m
ai
ni
ng
 sa
m
pl
es
.
Inhal Toxicol. Author manuscript; available in PMC 2017 December 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Stefaniak et al. Page 18
Ta
bl
e 
2
D
iss
ol
ut
io
n 
of
 in
di
um
 fr
om
 in
du
str
ia
lly
 sa
m
pl
ed
 p
ow
de
rs
 (n
 
=
 3
 sa
m
pl
es
 p
er
 c
el
l) 
in 
PS
F (
pH
 4.
5).
M
at
er
ia
lb
SS
A
 (m
2 /g
)c
El
em
en
t
C
um
 (%
)d
D
iss
ol
ut
io
n 
pa
ra
m
et
er
s (
M
ea
n ±
 St
an
da
rd
 de
v
ia
tio
n)
a
In
iti
al
 r
ap
id
 p
ha
se
La
tte
r 
slo
w
er
 p
ha
se
f r 
(%
)
t 1
/2
 
(d
)
s r
 
(d
−
1 )
f s (
%
)
t 1
/2
 
(d
)
s s
 
(d
−
1 )
In
2O
3
<
5
In
di
um
1.
87
 ±
 0
.5
5
0.
03
 ±
 0
.0
5
0.
41
 ±
 0
.6
0
7.
9 
± 
6.
4
10
0 
± 
0.
05
18
80
 ±
 2
66
3.
7 
± 
0.
5 
× 
10
−
4
SI
TO
3.
0 
± 
0.
1
In
di
um
4.
85
 ±
 0
.1
9
0.
11
 ±
 0
.1
0
0.
20
 ±
 0
.1
6
4.
7 
± 
2.
5
99
.9
 ±
 0
.1
41
7 
± 
18
1.
7 
± 
0.
0 
× 
10
−
3
V
D
1.
1 
± 
0.
0
In
di
um
15
.4
3 
± 
2.
36
8.
0 
± 
1.
5
0.
10
 ±
 0
.0
1
7.
1 
± 
0.
9
92
.0
 ±
 1
.5
25
1 
± 
85
3.
0 
± 
1.
2 
× 
10
−
3
a f
r 
an
d 
f s
 
=
 th
e 
pr
op
or
tio
n 
of
 th
e 
to
ta
l e
le
m
en
t d
iss
ol
ve
d 
in
 th
e 
in
iti
al
 ra
pi
d 
(f r
) o
r l
att
er 
slo
w
er
 (f
s) 
ph
ase
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r l
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=
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; S
IT
O
 =
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ed
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O
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 =
 v
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til
at
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st.
c S
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 =
 sp
ec
ifi
c 
su
rfa
ce
 a
re
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as
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te
d 
pr
ev
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us
ly
 (B
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ng
 e
t a
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4);
 <i
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tes
 th
at 
a p
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w
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 n
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to
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 c
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